The survey also found that flexible and virtual appointments, as well as transportation support, were helpful while on ...

At the European Cell and Gene Therapy Summit 2024, confidence in the sector’s maturity and progress was evident, highlighted ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

ViiV Healthcare, the specialist HIV company majority owned by GSK (LSE: GSK), today announced the presentation of new ...

Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

ViiV Healthcare sponsored events to address the climbing rates of HIV infections on HBCU campuses and the surrounding Black ...

ViiV Healthcare has announced plans to triple its annual supply of long-acting cabotegravir for HIV pre-exposure prophylaxis ...